Science and Technology

Azenta's New Genomic Laboratory in Oxford Elevates Local Science Capabilities

BURLINGTON, Mass., May 13, 2024 /PRNewswire/ -- In a major move towards enhancing genomics research capabilities in the United Kingdom, Azenta, Inc. (Nasdaq: AZTA) has officially announced the opening of its state-of-the-art Genomics Laboratory situated in Oxford, UK. This newly established laboratory is set to augment the GENEWIZ Multiomics & Synthesis Solutions' presence and cater to the scientific community residing within the UK. The primary aim of this location is to provide closer access to advanced next-generation sequencing (NGS) platforms and expertise, with the opportunity for UK-based researchers to collaborate with a local team comprising top-tier scientists renowned within the Oxford scientific ecosystem.

Dr. Ginger Zhou, the President of Azenta's Multiomics business unit, expressed her excitement, "We're ecstatic about the introduction of our Oxford laboratory, which will enable us to deliver technologically advanced NGS services directly to UK researchers. The establishment of this facility is more than just an expansion; it's a commitment to foster close relationships with the scientific community by offering them not only accessibility but also resources that are at the pinnacle of genomic research. Our Oxford team is composed of the finest minds who are not only experts in their field but are also deeply integrated with the local scientific infrastructure."

The inauguration event, which transpired on April 25, 2024, was commemorated through a ribbon-cutting ceremony, a comprehensive lab tour, and a celebratory gathering that brought together pivotal stakeholders such as local scientists, esteemed guests, and Azenta's top brass.

During this celebration, Dr. David Buck, the Director of Lab Services in Oxford, conveyed his thoughts, "This novel laboratory stands as a testament to our unwavering dedication to empowering UK scientists by providing swift, high-grade data dissemination. This support is set to enhance research and expedite advancements across vital health domains, including diabetes, infectious diseases, Alzheimer's, and more. We are geared up for the dynamic interaction and cooperation with the scientific fraternity and are eager to play a role in the achievements of their groundbreaking research endeavors."

Dr. John Todd, an acclaimed Professor of Precision Medicine at the University of Oxford, noted the facility's significant contribution to research progress, "With this impressive genomics laboratory now in place, we anticipate considerable acceleration in our research capabilities. This means achieving our goals with more speed, precision, and cost-effectiveness. It's facilities like these that boost our quest in making discoveries that have a real-world impact, particularly in advancing patient care."

A core focus of the Oxford Genomics Laboratory is convenience for the customer. With its strategic positioning, it offers a network of GENEWIZ collection points and ensures free, same-day dry ice sample collection in Oxford and Cambridge, thus simplifying the process of sample submission for researchers. The laboratory is designed to deliver an exhaustive spectrum of NGS services encompassing library preparation, sequencing, and bioinformatics analysis, supported by UK-based data storage. Additionally, it is on the brink of unveiling a selection of DNA/RNA extraction capabilities. Ph.D.-level study managers, armed with extensive experience, oversee projects from initiation to completion to ensure the highest quality of outcomes for the researchers.

Equipped with the latest advancements in NGS platforms, Azenta's GENEWIZ is poised to keep service users at the forefront of innovation. Amongst the sophisticated tools available are Illumina NovaSeq™ X Plus, PacBio Revio, Oxford Nanopore Technologies GridION, and the PromethION 2 Solo. Also available are 10x Genomics Chromium X, the Nanostring GeoMx® & nCounter®, and Olink® Protein Biomarker Detection platforms.

About Azenta Life Sciences

Azenta, Inc. (Nasdaq: AZTA) is a preeminent force in the life sciences sector with a global presence, instrumental in propelling significant breakthroughs and expediting the delivery of therapies to the market. Azenta is known for its suite of dependable cold-chain sample management solutions and a broad spectrum of multiomics services that cater to drug development, clinical research, and the burgeoning field of advanced cell therapies. This offering is propelled by Azenta's global team and is available under renowned industry-leading brands such as GENEWIZ, FluidX, Ziath, 4titude, Limfinity, Freezer Pro, Barkey, and B Medical Systems.

The company has its headquarters nestled in Burlington, MA, and operates across continents, including North America, Europe, and Asia. For further information about Azenta and its extensive service offerings, one can explore their website at www.azenta.com.

Investor Relations

Catering to the investment community, Azenta ensures transparent and proactive engagement. Yvonne Perron, who is the Vice President of Financial Planning & Analysis, as well as Investor Relations, is a primary contact for investor-related inquiries. Additionally, Sherry Dinsmore is available to address further queries from investors. Azenta underscores that its references to third-party trademarks and brands throughout their communications are solely for identification purposes and should not be taken as an affiliation or endorsement. These trademarks belong to their respective owners.

Yvonne Perron can be reached via email at [email protected], and those seeking assistance from Sherry Dinsmore can contact her at [email protected]

Azenta's commitment to innovation and excellence stands as a beacon for the life sciences industry. As genomic research continues to unravel mysteries and forge pathways to groundbreaking therapies, facilities like Azenta's new Genomics Laboratory in Oxford not only become hubs for scientific progression but also manifest as symbols of the relentless pursuit of knowledge and the betterment of mankind.

Source: Azenta

End of Article